Showing results (31-40 of 92) with videos related to
Sort By:
Pageof 10
Cancer Research|November 6, 2009
Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human gammadelta T cellsHamed Shojaei, Hans-Heinrich Oberg, Matthias Juricke, et al.Cancer Letters|September 13, 2003
Clinicopathological significance and molecular regulation of maspin expression in ductal adenocarcinoma of the pancreasNobuyuki Ohike, Nicolai Maass, Christoph Mundhenke, et al.Journal of Cancer Research and Clinical Oncology|August 3, 2013
Intra-operative use of one-step nucleic acid amplification (OSNA) for detection of the tumor load of sentinel lymph nodes in breast cancer patientsThorsten Heilmann, Micaela Mathiak, Jakob Hofmann, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 19, 2010
Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33)Sibylle Loibl, Volkmar Mueller, Gunter von Minckwitz, et al.International Journal of Clinical Oncology|November 18, 2015
Stromal markers AKR1C1 and AKR1C2 are prognostic factors in primary human breast cancerAntonia Wenners, Felix Hartmann, Arne Jochens, et al.BMC Cancer|August 10, 2010
In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cellsMarion T Weigel, Linda Dahmke, Christian Schem, et al.Journal of Cancer Research and Clinical Oncology|May 10, 2008
Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effectsChristoph Mundhenke, Marion Tina Weigel, Klarissa Hanja Sturner, et al.Acta Oncologica (Stockholm, Sweden)|October 5, 2019
Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancerAntroula Papakonstantinou, Elham Hedayati, Mats Hellström, et al.Anticancer Research|July 2, 2014
Significance of syndecan-1 expression in ductal carcinoma in situ of the breastKatharina Tiemann, Marion Tina Weigel, Ibrahim Alkatout, et al.Thrombosis and Haemostasis|June 6, 2007
Activated coagulation factors in human malignant effusions and their contribution to cancer cell metastasis and therapyFrank Gieseler, Inke Lühr, Thomas Kunze, et al.Pageof 10